Mark is a Managing Director and the group compliance leader at Epsilon Life Sciences and is based in Atlanta, GA. He advises clients in the U.S., Europe, South America, Africa and Asia on complex issues such as SEC financial accounting investigations, white collar crime allegations, Foreign Corrupt Practices Act matters, False Claims Act damages, violations of the Anti-Kickback Statute, pharmaceutical sales and marketing compliance, economic damages, global transparency, privacy and GDPR issues, risk assessments, auditing and monitoring assessments, and helping companies build and develop governance structures that are right-sized for the organization. He has also served as an expert witness and delivered deposition.
He has served in several secondments, including for over a year as the global Chief Compliance Officer for a multi-billion-dollar medical device and diagnostics company with over 50 world-wide locations, and for a mid-sized global pharmaceutical company and served as the U.S. Integrity & Compliance Officer and oversaw global sanctions. During these roles, he served on numerous approval committees including Grants, Donations, IME, Policy, and ESS. He helped build a comprehensive third-party due diligence system, sanctions screening program, and helped develop metrics for tailored management reporting.
Mark is also an Independent Review Organization (IRO) expert and serves as an advisor on state and federal healthcare compliance issues. He also has assisted in the development of alternative methodologies to help refute multi-billion-dollar claims brought forth by government agencies. Additionally, he has served as an expert witness in litigation in federal court.
Mark is a Certified Public Accountant (CPA) licensed in the state of Georgia, a Certified Fraud Examiner (CFE), and is Certified in Financial Forensics (CFF). He has spoken at large industry-specific, global compliance conferences on topics ranging from global transparency issues, research & development, U.S. and global privacy, ESG and sustainability, bribery and corruption, third-party due diligence programs, and data analytics and ethics.
